Delaet Ingrid 4

What Happened

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences (NBIX), had 801 restricted stock units (RSUs convert/vest) on January 31, 2026. The RSUs converted to 801 shares and the company withheld 475 shares to satisfy tax withholding obligations (withholding value $136.06/share; $64,629 total). No open‑market sale occurred — this was a vesting/tax withholding event, not a purchase or discretionary sale.

Key Details

• Transaction date: January 31, 2026 (reported on Form 4 filed Feb 3, 2026).
• Actions reported: M = conversion/exercise of derivative (801 shares acquired via RSU vesting at $0.00 per share); F = tax withholding (475 shares withheld/disposed at $136.06 per share; $64,629).
• Net shares delivered to the insider from this vesting: 801 − 475 = 326 shares.
• Total post-transaction beneficial ownership is not specified in the filing.
• Footnotes: Each RSU converts to one share. The RSU grant was made Jan 31, 2022 with a staggered vesting schedule (800 shares vested 1/31/2023; 800 on 1/31/2024; 801 on 1/31/2025; 801 on 1/31/2026). Shares were withheld by the company to meet tax withholding — no shares were sold on the open market.
• Filing timeliness: Form 4 was filed Feb 3, 2026. Because the vesting date fell on Jan 31, 2026, the filing appears to have been submitted within the required two business days.

Context

• This transaction is a routine RSU vesting and tax-withholding event (not a discretionary sale or open-market purchase). For derivative/RSU transactions, conversion followed by company withholding to cover taxes is common and does not necessarily indicate a change in insider sentiment.